These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8151315)

  • 1. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
    Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
    J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
    Jones SE; Khandelwal P; McIntyre K; Mennel R; Orr D; Kirby R; Agura E; Duncan L; Hyman W; Roque T; Regan D; Schuster M; Dimitrov N; Garrison L; Lange M
    J Clin Oncol; 1999 Oct; 17(10):3025-32. PubMed ID: 10506596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
    Miller LL; Korn EL; Stevens DS; Janik JE; Gause BL; Kopp WC; Holmlund JT; Curti BD; Sznol M; Smith JW; Urba WJ; Donegan SE; Watson TM; Longo DL
    Blood; 1999 May; 93(10):3250-8. PubMed ID: 10233876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.
    Vadhan-Raj S; Broxmeyer HE; Andreeff M; Bandres JC; Buescher ES; Benjamin RS; Papadopoulos NE; Burgess A; Patel S; Plager C; Hittelman WN; McAlister I; Garrison L; Williams DE
    Blood; 1995 Sep; 86(6):2098-105. PubMed ID: 7662957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
    Runowicz CD; Mandeli J; Speyer JL; Wadler S; Hochster H; Garrison L; Holland JF
    Am J Obstet Gynecol; 1996 Apr; 174(4):1151-9; discussion 1159-60. PubMed ID: 8623842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy.
    Vose JM; Anderson JE; Bierman PJ; Appelbaum FR; Anderson JR; Garrison L; Lebsack ME; Armitage JO
    J Clin Oncol; 1996 Feb; 14(2):520-6. PubMed ID: 8636766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells.
    Bishop MR; Jackson JD; O'Kane-Murphy B; Schmit-Pokorny K; Vose JM; Bierman PJ; Warkentin PI; Armitage JO; Garrison L; Kessinger A
    J Clin Oncol; 1996 Sep; 14(9):2521-6. PubMed ID: 8823331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen.
    Murren JR; Gollerkeri A; Anderson S; Lutzker S; Del Prete S; Zelterman D; Garrison L; Smith B
    Yale J Biol Med; 1998; 71(5):355-65. PubMed ID: 10527363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
    Furman WL; Rodman JH; Tonda ME; Luo X; Arnold B; Marina N; Garrison L; Hanna R; Pratt CB; Meyer WH
    Cancer Chemother Pharmacol; 1998; 41(3):229-36. PubMed ID: 9443640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
    Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
    Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
    Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
    Hovgaard DJ; Nissen NI
    J Clin Oncol; 1992 Mar; 10(3):390-7. PubMed ID: 1740678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
    O'Shaughnessy JA; Tolcher A; Riseberg D; Venzon D; Zujewski J; Noone M; Gossard M; Danforth D; Jacobson J; Chang V; Goldspiel B; Keegan P; Giusti R; Cowan KH
    Blood; 1996 Mar; 87(6):2205-11. PubMed ID: 8630380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer.
    Kobrinsky NL; Sjolander DE; Cheang MS; Levitt R; Steen PD
    J Clin Oncol; 1999 Nov; 17(11):3426-30. PubMed ID: 10550137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.